How to Value an Orthopedic Implant Distributor in 2026

Orthopedic implant distribution is a business built on two assets that don't show up on any balance sheet: the relationships your reps have with surgeons, and the strength of your contract with Stryker, Zimmer Biomet, or DePuy Synthes. I've valued dozens of ortho distributorships, and I can tell you that the financial statements tell maybe 40% of the story. The rest is locked inside your manufacturer agreement and inside the Rolodex of your top three sales reps.

This guide walks through how ortho implant distributors actually get priced in 2026, why the multiples look the way they do, and the specific things that can double or halve your exit value.

The Multiple Range: 4-6x EBITDA

Ortho implant distributors trade lower than general med device distributors for a simple reason: they live or die by a single manufacturer contract that can be terminated. The typical range is 4.0-6.0x adjusted EBITDA, with the strongest businesses occasionally reaching 6.5x.

• 4.0-4.5x EBITDA: Smaller territories, sub-$2M EBITDA, heavy rep dependence, contract with less than 3 years remaining.
• 4.5-5.0x EBITDA: Mid-size distributor, stable surgeon base, 3-5 years left on the manufacturer agreement, competitive territory.
• 5.0-5.5x EBITDA: Exclusive rights on trauma, spine, or joint reconstruction lines from a top-tier manufacturer, diversified surgeon mix across multiple hospitals and ASCs.
• 5.5-6.0x EBITDA: Multiple exclusive manufacturer relationships, $5M+ EBITDA, premium geographic territory (major metro with teaching hospitals), institutionalized rep structure.
• 6.0x+: Rare — usually reserved for distributors acquired by competitors who absorb the territory and eliminate overhead.

For context: compare this to the 4-7x range for broader medical device distributors. Ortho trades at the lower end because of the manufacturer concentration risk and the fact that most ortho distributors are essentially a one-product business.

The Manufacturer Contract Is Everything

Let me be direct: if you're an independent ortho distributor for Stryker, Zimmer Biomet, DePuy Synthes, Smith & Nephew, or one of the mid-tier players (Arthrex, Wright Medical, Enovis), your manufacturer contract is the single most important document in your business. Every buyer starts there.

The issues that drive pricing:

• Remaining term: Contracts with 5+ years remaining command full multiples. Contracts with under 2 years remaining get discounted by 1-1.5 turns.
• Change of control: Most major ortho manufacturers retain the right to terminate or renegotiate upon a sale. Buyers want written consent before closing.
• Territory exclusivity: Exclusive rights to a defined geography are worth a full turn more than non-exclusive arrangements.
• Product line breadth: A distributor carrying trauma, joint reconstruction, AND sports medicine for the same manufacturer is far more valuable than one carrying only a single category.
• Performance quotas: Aggressive growth quotas create termination risk. Buyers discount aggressively when quotas look unachievable.

In almost every ortho distributor deal I've worked on, the buyer has required a direct conversation with the manufacturer's VP of distribution before signing. That conversation usually determines whether the deal happens at all. If you're on bad terms with your manufacturer, fix it before going to market.

Why Surgeon Relationships Are the Hidden Asset

Orthopedic implants are chosen by the surgeon, not the hospital purchasing department. When a surgeon decides to use Stryker Triathlon knees for their total joints, they're really deciding to work with your rep — the person who shows up at 6am in the OR, knows the trays cold, and troubleshoots mid-case when a screw is stripped.

This creates a specific valuation problem: the value isn't in the company, it's in the reps. If your top three reps leave post-close, 50-70% of the surgeon relationships walk out the door with them. Buyers know this, and they structure deals to protect against it.

Expect to see:

• Rep retention bonuses funded by the seller: 15-25% of rep annual comp, held in escrow, paid out over 24 months for key reps who stay.
• Non-compete enforcement: Buyers will demand ironclad non-competes from the top producers before closing. If your reps won't sign, your deal is dead.
• Earn-outs tied to surgeon retention: 10-20% of purchase price tied to maintaining specific surgeon case volumes over 12-24 months.

The smartest sellers professionalize rep compensation structures 12-18 months before sale — converting pure commission reps to base-plus-bonus, layering in non-competes, and building institutional account management so surgeons interact with the company and not just one rep.

Adjusted EBITDA for Ortho Distributors

Calculating adjusted EBITDA for an ortho distributorship has a few industry-specific quirks. The standard add-backs apply — owner comp normalization, family on payroll, personal vehicles, discretionary travel. But watch out for:

Loaner tray depreciation. Your loaner instrumentation inventory is a real cost of doing business. Don't try to add back tray depreciation as a non-cash item. Sophisticated buyers know that loaner sets need constant replacement and they'll treat that CapEx as recurring.

Surgeon entertainment. Post-Sunshine Act, legitimate surgeon education, speaker programs, and society meetings are part of the cost structure. Don't add these back unless they're clearly extraordinary.

Rep commission timing. If you accrue commissions differently than the buyer will, adjust for the difference in the quality of earnings report rather than burying it in add-backs.

A clean QoE report from a reputable firm (Centri, CFGI, BDO, or similar) typically pays for itself 5-10x in preserved purchase price.

Who Buys Ortho Distributors

The buyer universe is smaller than for general device distribution. Three main pools:

The manufacturer itself. Stryker, Zimmer Biomet, and DePuy Synthes all occasionally buy their own distributors to go direct. This happens most frequently when a territory becomes strategically important (a major metro, a teaching hospital, a growing ASC market) or when the distributor's founder retires without a succession plan. Manufacturer acquisitions typically clear at the top of the range because the manufacturer captures the full distributor margin post-close.

Larger independent distributors. Roll-ups of ortho distributors have accelerated over the past decade. Groups like Xtant Medical and regional consolidators buy adjacent territories to build multi-state platforms. Pricing is typically 4.5-5.5x EBITDA for add-ons.

Private equity. PE interest in ortho distribution is narrower than in general device distribution because of the manufacturer dependence, but Harvest Partners, Bain Capital, and Linden Capital have all done ortho-adjacent deals. Platform multiples of 6-7x are possible for the right asset.

What Kills Value

Manufacturer relationship deterioration. If you're missing quota, your regional manager is talking about consolidating your territory, or you've had a product recall handled badly, buyers will find out and price it in.

Surgeon concentration. If one surgeon drives 25%+ of case volume, that's a massive discount. Orthopedic surgeons switch vendors more frequently than sellers want to admit.

ASC transition risk. Cases are moving from hospitals to ambulatory surgery centers rapidly, particularly total joints. If your distributor is still 90% hospital-based, buyers will discount for the transition risk.

Inventory and instrumentation condition. Old, damaged, or incomplete loaner trays mean the buyer has to reinvest. Every dollar of instrumentation CapEx the buyer identifies comes off the purchase price.

The Bottom Line

Ortho distribution is one of the harder niches to sell cleanly because the value depends on contracts and relationships you don't fully control. But the distributors that prepare well — by renegotiating manufacturer terms, retaining key reps, diversifying their surgeon base, and cleaning up instrumentation inventory — consistently exit at 5.5-6x EBITDA when the industry average is closer to 4.5-5x. That difference is often $3-5M of real money on a typical mid-size distributor. Start the preparation work two years before you plan to sell.